HT PARP In Vivo Pharmacodynamic Assay II Kit 4520B-096-K from R&D Systems, a Bio-Techne Brand

Product Specs
ItemHT PARP In Vivo Pharmacodynamic Assay II Kit
CompanyR&D Systems, a Bio-Techne Brand
Price $1,475.00Supplier Page View Company Product Page
Catalog Number4520B-096-K
StorageStore the unopened product at -20 to -70 °C. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Do not use past expiration date
NCBI Full Gene Namepoly(ADP-ribose) polymerase 1
NCBI Gene AliasesADPRT, ADPRT 1, ADPRT1, ARTD1, PARP, PARP-1, PARS, PPOL, Poly-PARP, pADPRT-1
Detection TargetPARP
Quantity1 Kit
ReactivityMulti-Species

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) BRCA2 reversion mutation-independent resistance to PARP inhibition through impaired DNA prereplication complex functionProc Natl Acad Sci U S AJune 10, 2025Kyrie Pappas, Matteo Ferrari, Perianne Smith, Subhiksha Nandakumar, Zahra Khan, Serina B. Young, Justin LaClair, Marco Vincenzo Russo, Emmet Huang-Hobbs, Nikolaus Schultz, et al.or 100 nM olaparib (LC Laboratories) for 7 d. Used PARP Pharmacodynamic ELISA Kit II (R&D Systems, 4520B-096-K) according to the manufacturers protocol for suspension cells to quantify PARP1 activity. Results were

(2) First-In-Human Dose Finding Study of Venadaparib (IDX-1197), a Potent and Selective PARP Inhibitor, in Patients With Advanced Solid TumorsCancer medicineFebruary 1, 2025Kim SB, Bae KS, Lee JL, Lee WS, Ock CY, Lee MJ, Bang J, Hong MJ, Roh EJ, Ha KS, et al.

(3) Central carbon metabolism exhibits unique characteristics during the handling of fungal patterns by monocyte-derived dendritic cellsRedox biologyJuly 1, 2024Alvarez Y, Mancebo C, Alonso S, Montero O, Fernández N, Sánchez Crespo M.

(4) Hydantoin based dual inhibitors of ALR2 and PARP-1: Design, synthesis, in-vitro and in-vivo evaluationBioorganic chemistryDecember 1, 2022Kumar M, Kumar Singh P, Choudhary S, Silakari O.

(5) Live Cell Detection of Poly(ADP-Ribose) for Use in Genetic and Genotoxic Compound ScreensCancersJuly 28, 2022Koczor CA, Haider AJ, Saville KM, Li J, Andrews JF, Beiser AV, Sobol RW.

(6) The three-dimensional structure of Epstein-Barr virus genome varies by latency type and is regulated by PARP1 enzymatic activityNature communicationsJanuary 17, 2022Morgan SM, Tanizawa H, Caruso LB, Hulse M, Kossenkov A, Madzo J, Keith K, Tan Y, Boyle S, Lieberman PM, et al.

(7) Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancerOncology lettersApril 1, 2020Ma Y, Chen P, Drisko JA, Khabele D, Godwin AK, Chen Q.

(8) Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses PreclinicallyMolecular cancer therapeuticsJanuary 1, 2020Riches LC, Trinidad AG, Hughes G, Jones GN, Hughes AM, Thomason AG, Gavine P, Cui A, Ling S, Stott J, et al.

(9) PARP1 is a versatile factor in the regulation of mRNA stability and decayScientific reportsMarch 6, 2019Matveeva EA, Mathbout LF, Fondufe-Mittendorf YN.

(10) Coupling of PARP1-mediated chromatin structural changes to transcriptional RNA polymerase II elongation and cotranscriptional splicingEpigenetics & chromatinFebruary 18, 2019Matveeva EA, Al-Tinawi QMH, Rouchka EC, Fondufe-Mittendorf YN.

(11) A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient miceTheranosticsJanuary 1, 2019Zhang D, Baldwin P, Leal AS, Carapellucci S, Sridhar S, Liby KT.

(12) A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor modelsOncotargetDecember 14, 2018Sun K, Mikule K, Wang Z, Poon G, Vaidyanathan A, Smith G, Zhang ZY, Hanke J, Ramaswamy S, Wang J.

(13) Epstein-Barr Virus Oncoprotein LMP1 Mediates Epigenetic Changes in Host Gene Expression through PARP1Journal of virologyOctober 1, 2016Martin KA, Lupey LN, Tempera I.

(14) Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast CancerClinical cancer research : an official journal of the American Association for Cancer ResearchJune 15, 2016Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, Gadi VK, Guenthoer J, Beumer JH, Korde L, et al.

(15) Global Transcriptome Analysis Reveals That Poly(ADP-Ribose) Polymerase 1 Regulates Gene Expression through EZH2Molecular and cellular biologyDecember 1, 2015Martin KA, Cesaroni M, Denny MF, Lupey LN, Tempera I.

(16) Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast CancerMolecular cancer therapeuticsApril 1, 2015Karginova O, Siegel MB, Van Swearingen AE, Deal AM, Adamo B, Sambade MJ, Bazyar S, Nikolaishvili-Feinberg N, Bash R, O'Neal S, et al.

(17) Base excision repair defects invoke hypersensitivity to PARP inhibitionMolecular cancer research : MCRAugust 1, 2014Horton JK, Stefanick DF, Prasad R, Gassman NR, Kedar PS, Wilson SH.

(18) Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analysesJournal of the National Cancer InstituteJune 1, 2014Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, et al.

(19) Implementation of validated pharmacodynamic assays in multiple laboratories: challenges, successes, and limitationsClinical cancer research : an official journal of the American Association for Cancer ResearchMay 15, 2014Kinders R, Ferry-Galow K, Wang L, Srivastava AK, Ji JJ, Parchment RE.

(20) Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivoMolecular cancer therapeuticsDecember 1, 2013Janzen DM, Paik DY, Rosales MA, Yep B, Cheng D, Witte ON, Kayadibi H, Ryan CM, Jung ME, Faull K, et al.

Be the First to Write a Review!

HT PARP In Vivo Pharmacodynamic Assay II Kit

HT PARP In Vivo Pharmacodynamic Assay II Kit from R&D Systems, a Bio-Techne Brand

R&D Systems, a Bio-Techne Brand

Citations (23)

Reviews

HT PARP In Vivo Pharmacodynamic Assay II Kit from R&D Systems, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map